Clinical Trials Logo

Thrombocytosis clinical trials

View clinical trials related to Thrombocytosis.

Filter by:

NCT ID: NCT06327100 Not yet recruiting - Clinical trials for Primary Myelofibrosis

Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

Start date: March 13, 2024
Phase: Phase 2
Study type: Interventional

To learn if tasquinimod either alone or in combination with ruxolitinib can help to control PMF, post-PV MF, or post-ET MF.

NCT ID: NCT06218628 Not yet recruiting - Clinical trials for Chronic Myelomonocytic Leukemia

Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition

Start date: April 1, 2024
Phase: Phase 1
Study type: Interventional

This is a prospective phase I dose-escalation study, with the primary objective to access the MTD and find the RP2D of talazoparib, given in combination with standard of care dosing of pacritinib.

NCT ID: NCT06150157 Recruiting - Neoplasms Clinical Trials

A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

Start date: December 20, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to characterize safety and to determine the Recommended Phase 2 Dose (RP2D[s]) and optimal dosing schedule(s) of JNJ-88549968, in part 1 (Dose Escalation); to characterize the safety of JNJ- 88549968 at RP2D(s), in part 2 (Cohort Expansion).

NCT ID: NCT06079879 Recruiting - Clinical trials for Essential Thrombocythemia

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

Start date: December 31, 2023
Phase: Phase 3
Study type: Interventional

This is a study evaluating the safety and efficacy of bomedemstat (MK-3543) compared with the best available treatment (BAT) in participants with essential thrombocythemia (ET) who have an inadequate response to or are intolerant of hydroxyurea. The primary study hypothesis is that bomedemstat is superior to the best available treatment with respect to durable clinicohematologic response (DCHR).

NCT ID: NCT06073847 Recruiting - Clinical trials for Primary Myelofibrosis

A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis

Start date: July 13, 2023
Phase:
Study type: Observational

The purpose of this study is to assess the real-world safety of fedratinib for the treatment of adult participants with primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), or post essential thrombocythemia myelofibrosis (post-ET MF) who were previously treated with ruxolitinib. Participants will represent the overall patient population with PMF, post-PV MF or post-ET MF who lost adequate response to and/or are intolerant to ruxolitinib. Inadequate response definitions will follow Ministry of Food and Drug Safety-approved label and reimbursement criteria of the Health Insurance Review & Assessment Service.

NCT ID: NCT06063486 Not yet recruiting - Clinical trials for Myelodysplastic Syndrome

Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms

Start date: April 1, 2024
Phase: Phase 2
Study type: Interventional

This phase II trial evaluates how a curcumin supplement (C3 complex/Bioperine) changes the inflammatory response and symptomatology in patients with clonal cytopenia of undetermined significance (CCUS), low risk myelodysplastic syndrome (LR-MDS), and myeloproliferative neoplasms (MPN). Chronic inflammation drives disease development and contributes to symptoms experienced by patients with CCUS, LR-MDS, and MPN. Curcumin has been shown to have anti-inflammatory and anti-cancer properties and has been studied in various chronic illnesses and hematologic diseases.

NCT ID: NCT05921838 Recruiting - Clinical trials for Primary Thrombocytosis

The Role of Circ0014614 in the Formation and Development of ET

Start date: January 1, 2021
Phase:
Study type: Observational

Research on the Role of Circ0014614 in the Formation and Development of ET

NCT ID: NCT05883904 Recruiting - Clinical trials for Primary Myelofibrosis

Real World Evidence of Fedratinib Effectiveness in MF

REALFed
Start date: January 29, 2024
Phase:
Study type: Observational

This is a multicenter prospective and retrospective observational clinical study in patients with primary or post polycythemia vera or post essential thrombocythemia myelofibrosis to test the efficacy of fedratinib in the rea world. Participants will be managed according to the clinical practice of the participating Center. All Centers will be Italian Hematology Units belonging to the GIMEMA Organization in Italy.

NCT ID: NCT05882773 Recruiting - Clinical trials for Primary Myelofibrosis

Asian Myeloproliferative Neoplasm (MPN) Registry

Start date: May 2023
Phase:
Study type: Observational [Patient Registry]

This is a multinational, multicenter, prospective and retrospective, observational, cohort study of patients with myeloproliferative neoplasm.

NCT ID: NCT05835466 Recruiting - Clinical trials for Post Essential Thrombocythemia Myelofibrosis (ET-MF)

Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)

Start date: June 27, 2023
Phase: Phase 2
Study type: Interventional

This is an open label, phase II study to assess the efficacy, safety, and tolerability of Reparixin in patients with DIPSS intermediate-2, or high-risk primary myelofibrosis (PMF), post essential thrombocythemia/polycythemia vera related MF (Post ET/PV MF) after prior treatment, and those who are ineligible or refuse treatment, with a Janus kinase inhibitor (JAKi). 26 patients will be enrolled. Eligible patients will receive oral reparixin three times daily on a 4-week cycle for a core study period of 6 cycles (24 weeks). After cycle 6, patients may continue receiving reparixin once daily on a 4-week cycle if at least stable disease (SD) is met by IWG-MRT criteria until loss of response, disease progression, unacceptable toxicity, patient/physician withdrawal, or termination of study by sponsor.